new, more potent and better tolerated antiretroviral drugs belonging to the 3 main classes (nucleoside reverse transcriptase inhibitors [NRTIs] , nonnucleoside reverse transcriptase inhibitors [NNRTIs] , and protease inhibitors [PIs] ) and also new antiretroviral classes with distinct mechanisms of action, such as integrase inhibitors (INIs).
Recent data from large randomized trials show high rates of control of HIV-1 replication (60%-80%) in both antiretroviral-naive [1] [2] [3] [4] [5] [6] [7] [8] [9] and previously treated patients [10] [11] [12] [13] [14] [15] [16] . However, the efficacy of new regimens is often assessed during relatively short periods and in selected populations with no ongoing opportunistic infections, few if any comorbidities (such as renal or hepatic failure), and good predicted adherence to treatment. Trends in virologic failure (VF) can help to evaluate the performance of healthcare systems and to assess the need for new combined antiretroviral therapy (cART) options. In addition, the proportion of patients with fully suppressed HIV replication correlates negatively with the potential burden of community viral load and has major implications for the reduction of ongoing HIV transmission [17] .
Four studies addressing trends in the effectiveness of ART have shown a decline in the frequency of VF [18] [19] [20] [21] , but one was conducted before 2006, when drugs from new classes started to appear [19] . We thought it was worthwhile to conduct a similar analysis in a setting where patient management and the use of antiretroviral drugs might differ. Thus, using data from the large French Hospital Database on HIV Infection (FHDH), we examined calendar trends in the rate of VF, the level of HIV-1 RNA at the time of VF according to study period, and factors associated with VF, between 1997 and 2011.
METHODS

Data Source
The FHDH clinical epidemiological network (FHDH-ANRS CO4) is a large prospective cohort involving 70 French hospitals. Patients are eligible for inclusion if they are infected by HIV type 1 or 2 and give their written informed consent. A standardized follow-up form is completed at each visit or hospital admission during which a new clinical manifestation is diagnosed or a new treatment is prescribed, or at least every 6 months. The FHDH has been approved by the French data protection authority (Commission Nationale de l'Informatique et des Libertés). Of note, in France, cART initiation and modifications have to be prescribed in the hospital setting. The FHDH has been shown to be representative of HIV-infected patients under care in France [22] . By the end of 2012, >128 000 HIV-infected patients who attended at least 1 follow-up visit between 1992 and December 2012 had been enrolled in the database.
Study Population
Patients were eligible if they were followed up between 1997 and 2011. We only included follow-up forms collected for patients who had received ART for at least 6 months. In case of treatment interruption, viremia follow-up was censored at the time of treatment discontinuation and resumed 6 months after treatment resumption, to avoid the risk that treatment interruptions (followed by viremia rebound) would artificially increase the rate of VF.
Statistical Analysis
VF was defined as 2 consecutive plasma HIV-RNA values ( pVL) >500 copies/mL at least 6 months after treatment initiation; or as 1 value >500 copies/mL >6 months after treatment initiation, followed by a treatment switch (ie, addition or replacement of at least 1 drug). The proportion of patients who experienced at least 1 VF during each 2-year period, and median pVL at the time of VF, were calculated with the patient as the unit of analysis ( Figure 1 , Table 1 ).
We then assessed the time trend in the rate of VF among patients during any of 5 consecutive 2-year calendar periods Figure 1 . Proportion of patients experiencing at least 1 virologic failure (VF) among patients having received antiretroviral therapy for at least 6 months. VF defined as 2 consecutive plasma HIV-RNA values >500 copies/mL at least 6 months after treatment initiation. Abbreviations: HIV, human immunodeficiency virus; IQR, interquartile range; pVL, plasma viral load. Table 2) . Two sensitivity analyses were conducted: the first excluding patients whose first-line regimen consisted of 1 or 2 NRTIs, and the other defining failure as a single pVL value >500 copies/mL; second using a threshold of 50 copies/mL from 2006, when all virological centers had adopted an HIV-1 RNA quantification assay with this lower threshold, the calendar effect being modeled yearly. 1-year period) was estimated to be 4.6%; 64.5% of these patients returned to an FHDH center later.
RESULTS
Characteristics of the Patients
Trend in VF From 1997 to 2011
As shown in Figure 1 , the proportion of patients experiencing at least 1 VF during each 2-year period fell continuously during the study period, from 61. The most recent CD4 cell count before VF correlated negatively with the risk of VF, with patients with counts >500 cells/ µL being significantly less likely to experience VF than those with counts of 350-499 cells/µL, 200-349 cells/µL, or <200/ µL (P < .0001) ( Figure 2B) .
Among all the antiretroviral regimens, no difference in the risk of VF was evidenced between a first-line treatment with 2 NRTIs plus INI-and NNRTI-containing regimen ( Figure 2C ), whereas the highest risk of VF was associated with a first-line mono-or dual-NRTI therapy.
We conducted a sensitivity analysis to test whether a similar improvement occurred in the subpopulation of patients who did not begin treatment with single-or dual-NRTI regimens. The proportion of the remaining patients who experienced at least 1 VF fell from 36.4% in 1997-1998 to 9.9% in 2009-2011. The results were similar to those of the main analysis with respect to the periods, CD4 cell counts, and treatment initiation. Similar results were also obtained in a second sensitivity analysis in which VF was defined as 1 VL value >500 copies/ mL: the proportion of patients experiencing VF fell from 75.2% in 1997-1998 to 13.6% in 2009-2011.
We also examined the time trend in the rate of VF beyond 6 months of treatment between 2006 and 2011, with VF being defined as 2 consecutive pVL >50 copies/mL or as 1 value >50 copies/mL followed by a treatment change. [23, 24] ; enfuvirtide in 2003 [25, 26] ; tipranavir in 2005 [27] ; and darunavir [28] , etravirine [11, 15] , raltegravir [10] , and maraviroc in 2008 [ Virologic control in heavily pretreated patients requires a salvage regimen including at least 2 active drugs, based on contemporary genotypic resistance testing [10, 28] . The use of innovative strategies combining new drugs was possible in France through early expanded access programs prior to market release [13] . These results are in keeping with those of other studies conducted in Europe and Canada. In the Royal Free cohort analyzed before new antiretroviral agents became available, among 2386 patients, the prevalence of pVL >50 copies/mL fell between 1999 and 2004, from 31.2% to 10.1% among patients receiving ART for 24 weeks or longer [19] . The UK Collaborative HIV Cohort showed a continuous improvement in the rate of virologic success ( pVL < 50 copies/mL), from 62% in 2000 to 84% in 2007 among >16 000 individuals [18] . In the Swiss cohort between 2000 and 2008, the proportion of patients with 3 consecutive pVL values <50 copies/mL rose from 37% to 64% among 10 213 patients [20] . Recently, the proportion of individuals achieving pVL suppression in British Columbia increased markedly, from 24% in 1997 to 80% in 2010 [21] .
One strength of our study is its large size (>81 000 patients) and lengthy follow-up (median, 9.4 years) with a median of 11 pVL values per patient, evenly distributed over the periods. In addition, the FHDH-ANRS CO4 cohort has been shown to be representative of patients under care in France [22] .
It is not easy to define VF in an observational setting over such a long period (from 1997 to 2011). Concomitant with improvements in the detection limits of VL assays, the definition of VF changed over time. For example, in France, the definition of VF was 500 copies/mL in 2006, but has been 50 copies/mL since 2008, whereas in the United States it was 50 copies/mL in 2006 and has been 200 copies/mL since 2011 [30] . For consistency, we defined VF as 2 consecutive VL values >500 copies/ mL or 1 VL value >500 copies/mL followed by a treatment switch, throughout the study period, as used in a recent study [21] . It is noteworthy that we obtained similar results with a VF definition of only 1 VL >500 copies/mL, as used in the Pursuing Later Treatment Option II study [31] , and also with a VF definition of 50 copies/mL during the period 2006-2011. The HIV-1 RNA level at VF fell significantly over time. Interestingly, among patients experiencing VF during the entire 15-year study period, the frequency of low-level viremia (500-1000 copies/mL) rose over time, representing one-third of failures in the most recent period. These lower pVL levels may be easier to suppress. However, such low-level HIV-1 replication might also lead to the selection of resistant variants [32] . Thus, recent French guidelines recommend rapid assessment and management of such failures, to avoid jeopardizing future therapeutic options [33] .
The annual rate of loss to FHDH follow-up was estimated to be 5.4% in 1999 [34] and was around 5% in each period investigated here. Patients lost to FHDH follow-up may continue to receive adequate care and cART, prescribed by their general practitioner or by a clinical center not participating in the cohort. In the Swiss HIV Cohort study, the favorable time trend persisted, albeit less pronounced, when such patients were considered to have experienced VF [20] . We restricted our analysis to patients with at least 6 months of cART exposure, because this is the time generally needed to reach a viral load <500 copies/mL among patients starting first-line cART and those resuming treatment after an interruption (the latter situation was far from rare prior to the premature termination of the Strategies for Management of Antiretroviral Therapy trial) [35] .
We found that the risk of VF was significantly higher when initial first-line ART consisted of 1 or 2 NRTIs; this risk decreased over time but still accounted for one-third of all VF in 2009-2011. The dramatic improvement in life expectancy among HIV-1-infected patients since 1996 is illustrated by the fact that 32% of the patients who experienced VF in 2009-2001 initially received mono-or dual-NRTI regimens and are still followed in clinical centers [36] [37] [38] .
The risk of VF was similar when first-line treatment consisted of 2 NRTIs plus 1 NNRTI or 1 INI, by comparison with 3 NRTIs; or 2 NRTIs plus 1 PI (boosted with ritonavir or unboosted). A regimen consisting of 2 NRTIs + NNRTI was chosen as the reference, because this combination was continuously recommended and used throughout the study period and has been the standard-of-care comparator in most major randomized trials assessing first-line triple-agent regimens. These results, obtained in a routine clinical setting and in a large population, are in line with those of randomized clinical trials in naive patients, which showed the lower virologic efficacy of triple-NRTI regimens [39] and of 2 NRTIs plus 1 ritonavirboosted PI [40] compared with 2 NRTIs plus either NNRTI or INI [41] [42] [43] . In addition, in highly pretreated patients, an INI-based salvage regimen was shown to achieve long-term viral suppression [14, 44] . It should be noted, however, that patients treated with NNRTI-or INI-based regimens may be at a higher risk of developing resistance (also in NRTI backbone) if VF occurs, by comparison to patients treated with boosted PIs, owing to the higher genetic barrier of the latter drugs [45] .
Lower contemporary CD4 cell counts were significantly associated with a higher risk of VF. Higher CD4 cell counts have previously been linked to better control of HIV-1 replication in clinical trials [2, 46] , possibly because they are usually associated with lower viral replication, which can be more easily suppressed. This emphasizes the need for earlier diagnosis and treatment of HIV infection [34] .
Interestingly, the risk of VF among patients originating from sub-Saharan Africa was similar to that among white patients in our study, reflecting the similar efficacy of cART on B and non-B HIV-1 subtypes. In addition, it should be noted that migrants living in France have good access to and retention in care. Contrary to some previous studies, we did not find that HCV coinfection was associated with a higher risk of VF [21] . In France, the seroprevalence of HCV coinfection is at least 92% among HIV-infected intravenous drug users [47] . The favorable outcome of HIV infection among HCV-coinfected patients in France might be linked to the launch of the buprenorphine and methadone replacement programs in 1995. Indeed, patients enrolled in such programs are seen and monitored frequently in dedicated clinical units, with good retention in care.
Overall, our results confirm the dramatic improvement in the outcome of HIV-1 infection in France over the last 15 years. The higher sensitivity of HIV-1 RNA assays is leading to more aggressive and effective management of resistance. Newgeneration antiretroviral drugs with better tolerability [1, 5-9, 42, 43] and a lower pill burden will likely further improve adherence to treatment. Finally, earlier treatment initiation at relatively high CD4 cell counts [30, 33] is likely to improve long-term virologic outcome.
In other countries-the United States, for example-49% patients do not remain under care, often for financial reasons [48] , whereas all treatments are provided free of charge in France, including for migrants. This may explain why 87% of French patients with known HIV infection are currently under care [38] . Similarly high rates of retention in care are also seen in other countries where ART is provided free of charge [49] . Thus, accessible and affordable healthcare, including new drugs and formulations, as well as close monitoring, are necessary to lower the global burden of HIV.
